The Journal of Korean Medicine (대한한의학회지)

The Society of Korean Medicine (대한한의학회)
권호 표지

Interpretation of Animal Dose and Human Equivalent Dose for Drug Development

  • Shin, Jang-Woo (Liver and Immunology Research Center, Institute of Traditional Medicine and Bioscience of Daejeon University) ;
  • Seol, In-Chan (Liver and Immunology Research Center, Institute of Traditional Medicine and Bioscience of Daejeon University) ;
  • Son, Chang-Gue (Liver and Immunology Research Center, Institute of Traditional Medicine and Bioscience of Daejeon University)
  • Received : 2009.11.24
  • Accepted : 2010.02.08
  • Published : 2010.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: To introduce to TKM scientific dose conversion methods of human to animal or animal to human for new drug investigations. Methods: We searched guidelines of the FDA and KFDA, and compared them with references for drug-dose conversion from various databases such as PubMed and Google. Then, we analyzed the potential issues and problems related to dose conversion in safety documentation of new herbal drugs based on our experiences during Investigational New Drug (IND) applications of TKM. Results: Dose conversion from human to animal or animal to human must be appropriately translated during new drug development. From time to time, investigators have some difficulty in determining the appropriate dose, because of misunderstandings of dose conversion, especially when they estimate starting dose in clinical or animal studies to investigate efficacy, toxicology and mechanisms. Therefore, education of appropriate dose calculation is crucial for investigators. The animal dose should not be extrapolated to humans by a simple conversion method based only on body weight, because many studies suggest the normalization method is based mainly on body surface area (BSA). In general, the body surface area seems to have good correlation among species with several parameters including oxygen utilization, caloric expenditure, basal metabolism, blood volume and circulating plasma protein. Likewise, a safety factor should be taken into consideration when deciding high dose in animal toxicology study. Conclusion: Herein, we explain the significance of dose conversion based on body surface area and starting dose estimation for clinical trials with safety factor.

Keywords

References

  1. Satoh N, Sakai S, Kogure T, Tahara E, Origasa H. Shimada Y, et al. A randomized double blind placebo-controlled clinical trial of Hochuekkito, a traditional herbal medicine, in the treatment of elderly patients with weakness N of one and responder restricted design. Phytomedicine. 2005;12:549-554. https://doi.org/10.1016/j.phymed.2004.06.014
  2. Matsumoto T, Moriya M, Kiyohara H, Tabuchi Y, Yamada H. Hochuekkito, a Kampo (Traditional Japanese Herbal) Medicine, and its Polysaccharide Portion Stimulate G-CSF Secretion from Intestinal Epithelial Cells. Evid Based Complement Alternat Med. 2008. doi:10.1093/ecam/nen007.
  3. Tajima S, Bando M, Yamasawa H, Ohno S, Moriyama H, Terada M, et al. Preventive effect of hochu-ekki-to, a Japanese herbal medicine, on bleomycin-induced lung injury in mice. Respirology. 2007;12:814-22. https://doi.org/10.1111/j.1440-1843.2007.01146.x
  4. Gad SC, Chengelis CP. Acute Toxicology: Principles and Methods. $2^{nd}$ rev. ed. San Diego, CA:Academic Press. 1998.
  5. Dreyer G, Ray W. The blood volume of mammals as determined by experiments upon rabbits, guinea pigs and mice and its relationship to the body weight and to the body surface area expressed as a formula. London: Phil. Trans. Royal Soc. 1910; 201:1330-60.
  6. Dreyer G, Ray W. Further experiments upon the blood volume of mammals and its relation to the surface area of the body. London: Phil. Trans. Royal Soc. 1912; 202:191- 212. https://doi.org/10.1098/rstb.1912.0006
  7. Best CH, Taylor NB. The Physiological Basis of Medical Practice. 4nd rev. ed. Baltimore: Williams & Wilkins. 1945:p525.
  8. Griffin G, Abbott W, Pride M, Muntwyler E, Mautz F, Griffith L. Plasma volume, "Available (Thiocyanate) Volume" and Total Circulating Plasma Proteins in Normal Adults. Ann Surgery. 1945; 121:352-60. https://doi.org/10.1097/00000658-194503000-00009
  9. FDA, Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. 2005.
  10. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966). Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966; 50:219-244.
  11. KFDA, Regulations on Registration and Licensing of Drug Products, Notification. No. 2009-42. 2009.
  12. KFDA, Guidelines to Clinical Study Authorization for Drugs, Notification. No. 2009-34, 2009.
  13. Wang XQ, Takahashi T, Zhu SJ, Moriya J, Saegusa S, Yamakawa J, et al. Effect of Hochuekki- to (TJ-41), a Japanese Herbal Medicine, on Daily Activity in a Murine Model of Chronic Fatigue Syndrome. Evid Based Complement Alternat Med. 2004;1:203-206. https://doi.org/10.1093/ecam/neh020